Literature DB >> 20179296

Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Marian L Neuhouser1, Cathee Till, Alan Kristal, Phyllis Goodman, Ashraful Hoque, Elizabeth A Platz, Ann W Hsing, Demetrius Albanes, Howard L Parnes, Michael Pollak.   

Abstract

Hyperinsulinemia and obesity-related metabolic disturbances are common and have been associated with increased cancer risk and poor prognosis. To investigate this issue in relation to prostate cancer, we conducted a nested case-control study within the Prostate Cancer Prevention Trial (PCPT), a randomized, placebo-controlled trial testing finasteride versus placebo for primary prevention of prostate cancer. Cases (n = 1,803) and controls (n = 1,797) were matched on age, PCPT treatment arm, and family history of prostate cancer; controls included all eligible non-whites. Baseline bloods were assayed for serum C-peptide (marker of insulin secretion) and leptin (an adipokine) using ELISA. All outcomes were biopsy determined. Logistic regression calculated odds ratios (OR) for total prostate cancer and polytomous logistic regression calculated ORs for low-grade (Gleason <7) and high-grade (Gleason >7) disease. Results were stratified by PCPT treatment arm for C-peptide. For men on placebo, higher versus lower serum C-peptide was associated with a nearly 2-fold increased risk of high-grade prostate cancer (Gleason >7; multivariate-adjusted OR, 1.88; 95% confidence interval, 1.19-2.97; P(trend) = 0.004). When C-peptide was modeled as a continuous variable, every unit increase in log(C-peptide) resulted in a 39% increased risk of high-grade disease (P = 0.01). In contrast, there was no significant relationship between C-peptide and high-grade prostate cancer among men receiving finasteride. Leptin was not independently associated with high-grade prostate cancer. In conclusion, these results support findings from other observational studies that high serum C-peptide and insulin resistance, but not leptin, are associated with increased risk of high-grade prostate cancer. Our novel finding is that the C-peptide-associated risk was attenuated by use of finasteride.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179296      PMCID: PMC3846551          DOI: 10.1158/1940-6207.CAPR-09-0188

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  73 in total

1.  Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002.

Authors:  Catherine C Cowie; Keith F Rust; Danita D Byrd-Holt; Mark S Eberhardt; Katherine M Flegal; Michael M Engelgau; Sharon H Saydah; Desmond E Williams; Linda S Geiss; Edward W Gregg
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

2.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

Authors:  Ian M Thompson; Chen Chi; Donna Pauler Ankerst; Phyllis J Goodman; Catherine M Tangen; Scott M Lippman; M Scott Lucia; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-08-16       Impact factor: 13.506

3.  Trends in hyperinsulinemia among nondiabetic adults in the U.S.

Authors:  Chaoyang Li; Earl S Ford; Lisa C McGuire; Ali H Mokdad; Randie R Little; Gerald M Reaven
Journal:  Diabetes Care       Date:  2006-11       Impact factor: 19.112

4.  Obesity, adipokines, and prostate cancer in a prospective population-based study.

Authors:  Jacques Baillargeon; Elizabeth A Platz; David P Rose; Brad H Pollock; Donna Pauler Ankerst; Steven Haffner; Betsy Higgins; Anna Lokshin; Dean Troyer; Javier Hernandez; Steve Lynch; Robin J Leach; Ian M Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

5.  Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.

Authors:  Nick Makridakis; Juergen K V Reichardt
Journal:  J Mol Endocrinol       Date:  2005-06       Impact factor: 5.098

6.  Proinsulin C-peptide stimulates a PKC/IkappaB/NF-kappaB signaling pathway to activate COX-2 gene transcription in Swiss 3T3 fibroblasts.

Authors:  Masashi Kitazawa; Yasutaka Shibata; Seiichi Hashimoto; Yasushi Ohizumi; Tohru Yamakuni
Journal:  J Biochem       Date:  2006-06       Impact factor: 3.387

7.  Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.

Authors:  Zhihong Gong; Marian L Neuhouser; Phyllis J Goodman; Demetrius Albanes; Chen Chi; Ann W Hsing; Scott M Lippman; Elizabeth A Platz; Michael N Pollak; Ian M Thompson; Alan R Kristal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

8.  The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity.

Authors:  Neal D Barnard; Anthony R Scialli; Gabrielle Turner-McGrievy; Amy J Lanou; Jolie Glass
Journal:  Am J Med       Date:  2005-09       Impact factor: 4.965

9.  Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation.

Authors:  Nomeli P Nunez; Won-Jun Oh; Julian Rozenberg; Chris Perella; Miriam Anver; J Carl Barrett; Susan N Perkins; David Berrigan; Jaideep Moitra; Lyuba Varticovski; Stephen D Hursting; Charles Vinson
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

10.  C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women.

Authors:  Esther K Wei; Jing Ma; Michael N Pollak; Nader Rifai; Charles S Fuchs; Susan E Hankinson; Edward Giovannucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-04       Impact factor: 4.254

View more
  18 in total

1.  Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 Diabetes.

Authors:  Wang Chen-Pin; Hernandez Javier; Carlos Lorenzo; John R Downs; Ian M Thompson; Bradley Pollock; Donna Lehman
Journal:  Ann Transl Med Epidemiol       Date:  2014

Review 2.  Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Authors:  Lori M Minasian; Catherine M Tangen; D Lawrence Wickerham
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

3.  Body size across the life course and prostate cancer in the Health Professionals Follow-up Study.

Authors:  Elisabeth Möller; Kathryn M Wilson; Julie L Batista; Lorelei A Mucci; Katarina Bälter; Edward Giovannucci
Journal:  Int J Cancer       Date:  2015-09-23       Impact factor: 7.396

Review 4.  Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?

Authors:  Jeff M P Holly; Li Zeng; Claire M Perks
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

5.  Metabolic imbalance and prostate cancer progression.

Authors:  Anya J Burton; Kate M Tilling; Jeff M Holly; Freddie C Hamdy; Mari-Anne E Rowlands; Jenny L Donovan; Richard M Martin
Journal:  Int J Mol Epidemiol Genet       Date:  2010-07-25

6.  Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study.

Authors:  Gabriel Y Lai; Kathy J Helzlsouer; Sandra L Clipp; Nader Rifai; Elizabeth A Platz
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-21

7.  Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS).

Authors:  Jeannette M Schenk; Marian L Neuhouser; Sarah J Beatty; Matthew VanDoren; Daniel W Lin; Michael Porter; John L Gore; Roman Gulati; Stephen R Plymate; Jonathan L Wright
Journal:  Contemp Clin Trials       Date:  2019-04-16       Impact factor: 2.226

Review 8.  Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer.

Authors:  Handoo Rhee; Ian Vela; Eric Chung
Journal:  Horm Cancer       Date:  2015-11-06       Impact factor: 3.869

9.  Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.

Authors:  Thomas U Ahearn; Sam Peisch; Andreas Pettersson; Ericka M Ebot; Cindy Ke Zhou; Rebecca E Graff; Jennifer A Sinnott; Ladan Fazli; Gregory L Judson; Tarek A Bismar; Jennifer R Rider; Travis Gerke; June M Chan; Michelangelo Fiorentino; Richard Flavin; Howard D Sesso; Stephen Finn; Edward L Giovannucci; Martin Gleave; Massimo Loda; Zhe Li; Michael Pollak; Lorelei A Mucci
Journal:  Carcinogenesis       Date:  2018-12-31       Impact factor: 4.944

10.  Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study.

Authors:  Gabriel Y Lai; Edward L Giovannucci; Michael N Pollak; Sarah B Peskoe; Meir J Stampfer; Walter C Willett; Elizabeth A Platz
Journal:  Cancer Causes Control       Date:  2014-03-25       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.